Company Filing History:
Years Active: 2001
Title: Pierre Caudrelier: Innovator in Transplant Medicine
Introduction
Pierre Caudrelier is a notable inventor based in Dardilly, France. He has made significant contributions to the field of transplant medicine, particularly through his innovative patent that addresses the challenges associated with organ transplants. His work focuses on improving patient outcomes and enhancing the longevity of transplants.
Latest Patents
Pierre Caudrelier holds a patent titled "Method for increasing mean survival times of transplants with LFA-1-specific antibodies." This patent describes a method that increases the mean survival times of functional solid organ transplants in patients. The approach involves administering an initial dose of a therapeutically effective amount of a monoclonal antibody directed against the human LFA-1 molecule within two hours after grafting, followed by daily doses for approximately nine days. This innovative method has the potential to significantly improve transplant success rates.
Career Highlights
Throughout his career, Pierre has been associated with Imtix-Sangstat, a company that focuses on developing therapies for transplant patients. His work at the company has allowed him to collaborate with other experts in the field and contribute to advancements in transplant medicine.
Collaborations
Pierre Caudrelier has worked alongside notable colleagues such as Gilles Alberici and Brigitte Le Mauff. Their collaborative efforts have furthered research and development in the area of transplant therapies.
Conclusion
Pierre Caudrelier's innovative contributions to transplant medicine, particularly through his patent on LFA-1-specific antibodies, highlight his commitment to improving patient care. His work continues to influence the field and offers hope for better transplant outcomes in the future.